International Aids Vaccine
The International AIDS Vaccine Initiative (IAVI) is a 501(c)(3) nonprofit scientific research organization headquartered at 125 Broad Street, 9th Floor, New York, NY 10004. Founded in 1996, IAVI develops vaccines and monoclonal antibodies for diseases with high unmet medical need, including HIV, tuberculosis, and emerging infectious diseases with pandemic potential that lack commercial incentives.
Financial Overview
From 2024 IRS Form 990-PF · View filing
Total Assets
$129.9M
+4.5% YoY
Annual Giving
$8.0M
-13.5% YoY
Grant Count
24
+4.3% YoY
Avg Grant Size
$331K
-17.1% YoY
Mission & Focus Areas
IAVI's mission is to translate scientific discoveries into affordable, globally accessible public health solutions. The organization was founded specifically to address the dire need for an HIV/AIDS vaccine to end the AIDS pandemic.
Primary Program Areas:
Research and Development: IAVI conducts scientific and clinical research in Africa, India, Europe, and the United States to develop vaccines and antibodies. The organization advances scientific discovery through unique collaborations among academia, industry, local communities, governments, and funders. Vaccine and antibody candidates undergo rigorous clinical evaluation among key populations to establish safety and efficacy. This work strengthens healthcare infrastructure and scientific capacity in countries where clinical partners operate. To date, IAVI and its partners have advanced dozens of HIV vaccine candidates into early-stage clinical trials, including vaccines that have yielded promising results.
Current Portfolio: IAVI is pioneering vaccine and monoclonal antibody development for HIV, tuberculosis, and emerging infectious disease threats with pandemic potential.
Grantmaking
According to the most recent filing data, IAVI distributed approximately **$33.7 million in total giving**. Grant awards typically range from $6,391 to $5,178,000, with average and median grant amounts varying by funding cycle.
Ready to take the next step with International Aids Vaccine?
Geographic Focus
Where this funder awards grants
IAVI conducts research and operations across multiple regions:
- Africa (including South Africa, Kenya, Zambia)
- India
- Europe
- United States
The organization operates in 10 countries total and maintains a presence in South Africa, Kenya, India, the Netherlands, and the United Kingdom.
Grant Distribution by State
States
Cities
Financial History
Multi-year comparison from IRS filings
As of December 2023:
| Metric | Amount |
|---|---|
| Total Revenue | $129.7 million |
| Total Expenses | $132.9 million |
| Total Assets | $124.2 million |
| Total Liabilities | $60.3 million |
Workforce: IAVI employs 233 people as of the most recent reporting period, with operations spanning multiple countries.
Financial Rating: IAVI received a Three-Star rating from independent charity evaluators, with an overall score of 89%, indicating strong accountability and financial management.
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Total Assets | $129,852,638 | $124,233,943 | $128,948,484 |
| Revenue | $131,181,475 | $129,678,400 | $146,782,280 |
| Expenses | $143,043,595 | $132,896,237 | $131,188,762 |
| Qualifying Distributions | — | — | — |
| Net Investment Income | $2,295,284 | $2,762,423 | $-178,814 |
| Distributable Amount | — | — | — |
Giving Over Time
Total grant dollars and number of grants per year
Grant Insights
How this funder distributes its grants
Top Recipients
Top 10 recipients in 2024
Grant Size Distribution
105 grants across all recorded years
Giving History
Grant recipients and amounts by year
No grants recorded for .
Leadership & Key People
Leadership team and compensation from IRS filings
Key executives include:
- Sandeep Mathur – Associate Director
- Min Ding – General Counsel
- Gaudensia Mutua – Medical Director
- Gretchen Meller – Senior Director, Project Management
- Esther Mungai-okech – Senior Director, Global Access
- Harriet Park – Executive Director, Global Clinical Operations
Compensation Overview
From 2024 IRS filing
From 2024 filing
| Name | Title | Hours | Compensation |
|---|---|---|---|
| MARK B FEINBERG | PRESIDENT/CEO | 35 | $718,500 |
| ERIC PAUL GOOSBY | BOARD CHAIR | 2 | — |
| ROBERT GOLDBERG | BOARD TREASURER | 2 | — |
| LINDA-GAIL BECKER | BOARD MEMBER | 1 | — |
| DAVID BLUMBERG | BOARD MEMBER | 1 | — |
| JIM CONNOLLY | BOARD MEMBER | 1 | — |
| MARK DYBUL | BOARD MEMBER | 1 | — |
| WAFAA EL-SADR | BOARD MEMBER | 1 | — |
| ALEXIS M PINTO | BOARD MEMBER | 1 | — |
| JOHN W SHIVER | BOARD MEMBER | 1 | — |
| SUSAN SILBERMANN | BOARD MEMBER | 1 | — |
| ANNE MARTIN SIMONDS | BOARD MEMBER | 1 | — |
| RAJEEV VENKAYYA | BOARD MEMBER | 1 | — |
| MARIJKE WIJNROKS | BOARD MEMBER | 1 | — |
| ANA CESPEDES MONTOYA | CHIEF OPERATING OFFICER | 35 | $552,506 |
| MARIO GAGLIANO | CHIEF PEOPLE OFFICER, VP OF HR | 35 | $364,310 |
| MIN DING | GENERAL COUNSEL/BOARD SECRETARY | 35 | $368,570 |
| LOUIS D SCHWARTZ | ASST. SEC., CHIEF FIN. & ADMIN OFF. | 35 | $353,545 |
| BRANDON SAFT | DEPUTY CHIEF FINANCIAL OFFICER | 35 | $255,811 |
| SWATI GUPTA | VP, HEAD OF EID AND EPIDEMIOLOGY | 35 | $402,341 |
| CHRISTOPHER PARKS | ASS. VP, VIRAL VACC. & HEAD OF DDL | 35 | $380,753 |
| DAGNA LAUFER | VP AND HEAD OF CLINICAL DEVELOPMENT | 35 | $402,844 |
| MARION GRUBER | VP, PUBLIC HEALTH & REG. SCIENCE | 35 | $383,236 |
| SANGEETHA SAGAR | VICE PRESIDENT, PDC | 35 | $384,858 |
Recent News & Activity
Recent developments and announcements
IAVI has been actively involved in major HIV vaccine research initiatives:
ZAMBIA TO BENEFIT FROM A USAID $45 MILLION GRANT FOR HIV VACCINE RESEARCHUSAID awarded $45 million to African scientists developing HIV vaccines, with IAVI as a partner organization
USAID awards $45 Million to African scientists developing HIV vaccineNIH awarded $31 million for HIV/AIDS vaccine immunology and immunogen discovery
USAID awards $45 Million to African scientists developing HIV vaccineIAVI launched a Phase 1 clinical trial of an HIV vaccine in Africa to evaluate immune responses to highly networked HIV T-cell epitopes
USAID awards $45 Million to African scientists developing HIV vaccineZambia received a USAID $45 million grant for HIV vaccine research and development, with IAVI involvement
USAID awards $45 Million to African scientists developing HIV vaccineSubject Areas
Focus areas based on grantmaking activity
Related Funders
Similar funders by location and focus area
Launa Beuhler Foundation for
BROOKLYN, NY
Assets
$2K
Grants
4
Total Given
$20K
Uw E J Madden Mem Open Hearts Club 10-214880
NEW YORK, NY
Assets
$1.3M
Grants
1
Total Given
$307K
Hindy's Foundation
BROOKLYN, NY
Assets
$142K
Grants
8
Total Given
$225K
Jeanne & Thomas Hardy Family Foundation
NEW YORK, NY
Assets
$3K
Grants
3
Total Given
$3K
Ramsleg Foundation
BRIGHTWATERS, NY
Assets
$543
Grants
1
Total Given
$500
Druckenmiller Foundation
NEW YORK, NY
Assets
$1.8B
Grants
58
Total Given
$135.7M
Data last updated April 2026. Sourced from IRS Form 990-PF filings. Research dossier generated April 2026.
What could you do with International Aids Vaccine on Grantable?
- Assess strategic fit with your organization
- Draft a tailored letter of inquiry
- Find open RFPs from this funder
- Monitor for new funding opportunities